# US 2022/0033456 A1 · T-cell modulatory multimeric polypeptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033456 A1
- Document ID: US20220033456A1
- Status: Published application
- Kind: A1
- Application number: 17/507,113
- Filed: 2021-10-21
- Published: 2022-02-03
- Earliest claimed: 2016-12-22
- Assignees: Cue Biopharma, Inc.
- Applicants: Cue Biopharma, Inc.
- Inventors: Ronald D. Seidel, III; Rodolfo J. Chaparro
- Web page: https://patentgrep.com/patent/US20220033456A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/55: IL-2
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55533: {IL-2}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

## Claims

### Claim at position 1

-132. (canceled)

### Claim 133

A heterodimer comprising:
a) a first polypeptide comprising:
i) a cancer-associated epitope other than a human papillomavirus epitope; and
ii) a first major histocompatibility complex (MHC) Class I polypeptide, wherein the first MHC polypeptide is a β2-microglobulin (β2M) polypeptide comprising an amino acid sequence having at least 95% percent amino acid sequence identity to amino acids 21 to 119 of SEQ ID NO:95, wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST, and
b) a second polypeptide comprising:
i) two copies of an IL-2 polypeptide, each copy comprising the amino acid sequence of SEQ ID NO: 84, wherein the two IL-2 polypeptides are linked by a peptide linker;
ii) a second MHC polypeptide, wherein the second MHC polypeptide is an MHC Class I HLA-A heavy chain polypeptide; and
iii) an immunoglobulin (Ig) Fc polypeptide, and
wherein the heterodimer comprises a disulfide bond that covalently links a Cys residue in the β2M polypeptide to a Cys residue in the MHC class I heavy chain polypeptide.

### Claim 134 (depends on 133)

A heterodimer according to claim 133, wherein
the Ig Fc polypeptide is an IgG1 Fc polypeptide having at least about 95% percent amino acid sequence identity to SEQ ID NO:57, wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST, and comprises an L14A substitution and an L15A substitution based on the amino acid numbering depicted in SEQ ID NO:57,
the second polypeptide comprises a peptide linker between one or more of:
a) a first copy of the IL-2 polypeptide and a second copy of the IL-2 polypeptide;
b) one of the two copies of the IL-2 polypeptide and the MHC class I heavy chain polypeptide; and
c) the MHC class I heavy chain polypeptide and the IgG1 Fc polypeptide.

### Claim 135 (depends on 133)

A heterodimer according to claim 133, wherein
the first and second polypeptides are covalently linked to one another via a disulfide bond between (i) a Cys residue at amino acid 12 of the β2M) polypeptide and (ii) a Cys at residue 236 of the MHC class I HLA-A heavy chain polypeptide based on the numbering depicted in SEQ ID NO:19.

### Claim 136 (depends on 133)

A homodimer comprising two heterodimers according to claim 133, wherein the two heterodimers are joined to each other by one or more disulfide bonds that join the Ig Fc polypeptide of one heterodimer to the Ig Fc polypeptide of the other heterodimer.

### Claim 137 (depends on 134)

A homodimer comprising two heterodimers according to claim 134, wherein the two heterodimers are joined to each other by one or more disulfide bonds that join the Ig Fc polypeptide of one heterodimer to the Ig Fc polypeptide of the other heterodimer.

### Claim 138 (depends on 135)

A homodimer comprising two heterodimers according to claim 135, wherein the two heterodimers are joined to each other by one or more disulfide bonds that join the Ig Fc polypeptide of one heterodimer to the Ig Fc polypeptide of the other heterodimer.

### Claim 139 (depends on 133)

A pharmaceutical composition comprising a heterodimer of claim 133.

### Claim 140 (depends on 134)

A pharmaceutical composition comprising a heterodimer of claim 134.

### Claim 141 (depends on 135)

A pharmaceutical composition comprising a heterodimer of claim 135.

### Claim 142 (depends on 136)

A pharmaceutical composition comprising a homodimer of claim 136.

### Claim 143 (depends on 137)

A pharmaceutical composition comprising a homodimer of claim 137.

### Claim 144 (depends on 138)

A pharmaceutical composition comprising a homodimer of claim 138.

### Claim 145 (depends on 142)

A method of treating cancer in a patient in need of such treatment, the method comprising administering a pharmaceutical composition of claim 142 to the patient in an amount effective to treat said cancer.

### Claim 146 (depends on 145)

The method according to claim 145, wherein the homodimer is administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 147 (depends on 145)

The method according to claim 145, wherein the homodimer is administered in an amount of from about 5 mg/kg to about 10 mg/kg of body weight.

### Claim 148 (depends on 143)

A method of treating cancer in a patient in need of such treatment, the method comprising administering a pharmaceutical composition of claim 143 to the patient in an amount effective to treat said cancer.

### Claim 149 (depends on 148)

The method according to claim 148, wherein the homodimer is administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 150 (depends on 148)

The method according to claim 148, wherein the homodimer is administered in an amount of from about 5 mg/kg to about 10 mg/kg of body weight.

### Claim 151 (depends on 144)

A method of treating cancer in a patient in need of such treatment, the method comprising administering a pharmaceutical composition of claim 144 to the patient in an amount effective to treat said cancer.

### Claim 152 (depends on 151)

The method according to claim 151, wherein the homodimer is administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 153 (depends on 151)

The method according to claim 151, wherein the homodimer is administered in an amount of from about 5 mg/kg to about 10 mg/kg of body weight.
